PRIORITY REVIEW AND ACCELERATED APPROVAL OF REGISTRATION / MARKET AUTHORIZATION

Document History: 1st Edition

Effective Date:

Drug Regulatory Authority of Pakistan
Islamabad-Pakistan
1. HISTORY

This is the first edition of these guidelines.

2. APPLICATION - Guideline for Industry

This document is applicable to manufacturers and importers for guidance on the eligibility criteria and mechanism for registration / market authorization of drugs that address the unmet medical needs in special situation (i.e. Public health emergency), orphan medicinal products or innovative therapies through priority review of submission and accelerated approvals.

3. PURPOSE

This document is meant to provide guidance to industry and healthcare professionals in elaboration of policy, eligibility criteria and procedure for registration / market authorization of pharmaceutical and biological drugs that address the unmet medical needs in special situation (i.e. Public health emergency), orphan medicinal products and innovative therapies, through priority review of submission and accelerated approvals.

The priority review mechanism provides a specific pathway for faster assessment and availability of vital lifesaving drugs to enhance access. The guidelines are intended to provide technical support for registration requirement and procedure for submission of application for expedited registration of pharmaceutical and biological products (including vaccines) of all types, which fulfil the criteria for priority review and accelerated approvals.
# Table of Contents

1. HISTORY ........................................................................................................................................2

2. APPLICATION - Guideline for Industry .........................................................................................2

3. PURPOSE .......................................................................................................................................2

4. INTRODUCTION ...........................................................................................................................4

5. LEGAL PROVISIONS ....................................................................................................................4

6. GENERAL CONSIDERATIONS ........................................................................................................5

7. EXPEDITED PATHWAYS FOR REGISTRATION / MARKET AUTHORIZATION ..............................5

7.1. GENERAL CONDITIONS FOR EXPEDITED PATHWAYS FOR REGISTRATION / MARKET AUTHORIZATION .................................................................................................................................5

7.2. PRIORITY REVIEW OF SUBMISSION ........................................................................................6

7.2.1. APPLICANT’S REQUEST FOR PRIORITY REVIEW OF SUBMISSION .........................6

7.2.2. PRIORITY REGISTRATION PROCESS ..............................................................................7

7.3. CONDITIONAL MARKETING AUTHORIZATION / REGISTRATION ....................................9

7.3.1. APPLICANT’S REQUEST FOR CONDITIONAL MARKETING AUTHORIZATION / REGISTRATION .................................................................................................................................9

7.3.2. CONDITIONAL MARKETING AUTHORIZATION / REGISTRATION APPLICATION PROCESS .................................................................................................................................9

GLOSSARY ........................................................................................................................................11

REFERENCE: ....................................................................................................................................13
4. INTRODUCTION

Pharmaceutical and Biological Drug Products are required to obtain registration / market authorization certificate to be put on the market legally in the country. The ultimate purpose of drug registration / market authorization is to ensure that safe, effective and quality drug products can be made available to the citizen.

Registration Board established under Section 7 of the Drug Act, 1976, along with Pharmaceutical Evaluation & Registration (PE&R) Division and Biological Evaluation & Research Division working under Section 4 of DRAP Act, 2012, is responsible for evaluation of application dossiers and granting registration / market authorization.

Drug Regulatory Authority of Pakistan (DRAP) recognizes that there are circumstances in which standard requirement and procedure for registration / market authorization may be challenging to fulfil and there is an unmet need of such drugs in the country. In such situations, DRAP supports the availability through registration of drug products that address the unmet medical needs in special situations. In such cases, application dossier submission is considered for priority review and / or applicants may be granted a conditional registration / marketing authorization for such drug products where the benefits of immediate availability outweigh the risk of less comprehensive data than normally required.

5. LEGAL PROVISIONS

Drug Regulatory Authority of Pakistan (DRAP) under Section 7 (u) of DRAP Act, 2012 perform the functions of registration of drugs. Drug are registered under Section 7 (1) of Drugs Act, 1976 as per the procedure for submission of product registration application provided under Rule 26 of Drugs (Licensing, Registering and Advertising) Rules, 1976.

Registration Board has already decided to consider the application dossier for those drugs through priority review process, indicated for treatment of chronic ailments which are short in availability including drugs for treatment of cancer, viral diseases, thalassemia, immunosuppressants, vaccines and sera, new molecules / formulation (therapies) and blood factors.

These guidelines conform to DRAP Act, 2012 and the Drugs Act 1976 and rules framed there under.
6. GENERAL CONSIDERATIONS

Priority Review and Accelerated approval of Registration / Market Authorization processes are expedited pathways, devised in line with best regulatory practices in the interest of public health. These processed are designed to provide enhance access to vital lifesaving drug product to address an unmet medical needs or address a situation in public health urgency. These processes are appropriate only for those products for which the benefit-risk balance of immediate availability outweighs the risks.

Applicant is responsible for providing all the necessary information in a timely manner. If the applicant cannot meet this requirement, DRAP may convert the submission to the standard registration process.

7. EXPEDITED PATHWAYS FOR REGISTRATION / MARKET AUTHORIZATION

DRAP has adopted following two pathways for expedited registration / market authorization of drug products which fulfill the criteria provided below under relevant pathway:--

A. Priority Review of Submission
B. Conditional Marketing Authorization

Applicant is invited to submit request about its intention to DRAP for consideration under appropriate expedited pathways for registration / market authorization, if the products fulfill the relevant criteria specified in these guidelines. For this purposes, the applicant shall submit a “Letter of Intent” addressed to Secretary Registration Board prior to submission of application dossier, in order to determine the eligibility of application for relevant expedited pathway.

7.1. GENERAL CONDITIONS FOR EXPEDITED PATHWAYS FOR REGISTRATION / MARKET AUTHORIZATION

Following eligibility criteria for priority determination are designed to ensure that only medicines providing the most beneficial are eligible. The eligibility criteria are:

✓ the benefit-risk balance of the product is positive;
✓ unmet medical needs will be followed;
✓ the benefit to public health of the drug product’s immediate availability on the market outweighs the risk;
it is likely that the applicant will be able to provide comprehensive data.

A determination process will be used to assess the eligibility of a product for the expedited pathway, however the designation of an application to the expedited pathways does not necessarily mean that the product will be approved after evaluation and registered by the Registration Board.

7.2. PRIORITY REVIEW OF SUBMISSION

Priority review of submission pathways is intended to shorten the assessment timeline. It provides patients and healthcare professional with faster access to new drug products and advanced drugs/therapies. Priority review is based on full dossier along with substantial evidence of quality, safety and efficacy.

The eligibility criteria for priority review of submission pathways are as follows:-

   I. Orphan medicines for the treatment of rare diseases
   II. New drug molecule / New indication drug
   III. Short availability
   IV. Serious condition e.g. outbreak of a disease etc.

7.2.1. APPLICANT’S REQUEST FOR PRIORITY REVIEW OF SUBMISSION

Applicant must first apply for priority determination before lodging a registration application. The application for priority determination should be no more than 10 pages and should address the following:-

   a) justification for addressing the general conditions for expedited pathway for registration / market authorization
   b) Fulfilling of eligibility criteria for Priority review
   c) Regulatory status in the reference regulatory authorities

In one application, drug products have same pharmaceutical ingredients / Drug substance can be combined. However, for multiple drug products, applicant is required to submit separate applications. Priority determination application will be addressed to the Secretary, Registration Board.
7.2.2. PRIORITY REGISTRATION PROCESS

Priority review is based on a full dossier and substantial evidence. A formal Application dossier in the prescribed format (i.e. Form-5F for human products, or Form-5/5A for veterinary products, as appropriate) shall be submitted. Priority review registration process is similar to the standard registration process except that the timeline for assessment and evaluation of dossier is aimed to reduce within a target timeframe of 150 **working days**.

The timeframe is calculated after priority determination process, from acceptance of application dossier for evaluation through to the decision of Registration Board.

Applicant is responsible for providing DRAP with all necessary information in a timely manner. If applicant cannot meet this requirement, application will be considered pending on the part of applicant.
A mutual stop-clock will be applied during evaluations / assessment rounds and the applicant is expected to submit responses within a timeframe of 14 working days. Firm may receive questions throughout the evaluation period as soon as the evaluators have questions arising from their assessments. Given the nature of the evaluation process, it is not possible to predict in advance when questions will be asked during the period of the assessment.
7.3. CONDITIONAL MARKETING AUTHORIZATION / REGISTRATION

For products intended for use in emergency situations, less comprehensive pharmaceutical and non-clinical data may also be accepted in special situation of public health urgency. For example legalized copy of administrative documents (e.g. CoPP, etc.) may be accepted later. Drug products / formulation which are not yet registered can only be applied for conditional marketing authorization while fulfilling the following criteria.

I. Drug Product is aimed at treating, preventing or diagnosing Seriously debilitating or life-threatening disease and not registered previously
II. Drug product required in public health emergency and not registered previously

7.3.1. APPLICANT’S REQUEST FOR CONDITIONAL MARKETING AUTHORIZATION / REGISTRATION

Applicant must first apply for determination of suitability for conditional marketing authorization / registration before lodging an application dossier. The application for determination of suitability should be no more than 10 pages and should address the following:-

a) justification for addressing the general conditions for expedited pathway for registration / market authorization;
b) justification for addressing eligibility criteria for conditional marketing authorization / registration ;
c) regulatory status in reference regulatory authorities

In one application, drug products have same pharmaceutical ingredients / Drug substance can be combined. However, for multiple drug products, applicant is required to submit separate applications. Priority determination application will be addressed to the Secretary, Registration Board.

7.3.2. CONDITIONAL MARKETING AUTHORIZATION / REGISTRATION APPLICATION PROCESS

Applicants for a conditional marketing authorization are advised to engage in early dialogue with DRAP to discuss their product development plan well in advance of the submission of a registration / marketing-authorization application.
For products deemed suitable for a conditional marketing authorization, applicants are also encouraged to consider requesting for priority review of submission.

A formal Application dossier should be submitted on prescribed format (i.e. Form-5F for human products, or Form-5/5A for veterinary products, as appropriate) with supporting documents to request for a conditional marketing authorization / registration. The application dossier will be evaluated by the assessors of DRAP in the light of approved SOPs. The evaluation report will be presented before the Registration Board.

The Registration Board consider the application dossier with evaluation report and decide whether the data submitted fulfill the requirements to justify that the benefit to public health of the drug product’s immediate availability on the market outweighs the risk. The Registration Board may consider to grant conditional marketing authorization / registration and may specify certain obligations regarding the product with its decision.

The applicant will be required to complete specific obligations (e.g. ongoing or new studies, and in some cases additional activities) with a view to providing comprehensive data confirming that the benefit-risk balance is positive.

If a conditional marketing authorization is granted, the specific obligations and deadlines for their completion will be specified in the marketing authorization. DRAP may also make these conditions publicly available for information of healthcare professional.

Registration Board may consider to grant a registration / marketing authorization in absence of comprehensive data under exceptional circumstances or public health emergency.
GLOSSARY

Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>DS</td>
<td>Drug Substance</td>
</tr>
<tr>
<td>DRAP</td>
<td>Drug Regulatory Authority of Pakistan</td>
</tr>
<tr>
<td>FDP</td>
<td>Finished Drug Product</td>
</tr>
<tr>
<td>MAH</td>
<td>Marketing Authorization Holder</td>
</tr>
<tr>
<td>PE&amp;R</td>
<td>Pharmaceutical Evaluation &amp; Registration Division</td>
</tr>
<tr>
<td>QSE</td>
<td>Quality, Safety and Efficacy</td>
</tr>
</tbody>
</table>

Definitions

Life-threatening condition

A condition where the prominent feature (i.e. affecting an important portion of the target population) is serious illness from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of treatment based on mortality and life expectancy data.

Seriously debilitating condition

A condition that has a prominent feature (i.e. affecting an important portion of the target population) which is morbidity with a well-established, major impact on the functioning of the person based on objective and quantifiable medical or epidemiologic information. Short-lived and/or self-limiting morbidity is not considered seriously debilitating.

Marketing Authorization (MA)

A document issued by the Registration Board set up under the Drugs Act, 1976, as a certificate of drug registration.

Marketing Authorization Holder / Registration Holder

Any person or legal entity that has received marketing authorization / registration to manufacture and/or distribute a finished drug product in the country. It also refers to a person or legal entity allowed to apply for a change to the marketing authorization or registration.
Registration Board (RB)

A board set up under Section 7 of the Drugs Act, 1976.

Reference Regulatory Authorities (RRA)

As adopted by Registration Board in its 275th meetings.
REFERENCE:

4. WHO Emergency Use Assessment and Listing Procedure (EUAL) for candidate medicines for use in the context of public health emergency.
5. EU Guideline on the conditional marketing authorisation for medicinal products for human use.